RealMind Biotech Asia

RealMind Biotech is a China-based biotechnology startup that has made significant strides since its founding in 2015. The company serves as a CDMO Service Supplier for Chemiluminescence Immunoassy (CLIA) System and has emerged as a leading CLIA system provider in China. RealMind has secured NMPA Certificates for 3 models of fully auto CLIA analyzers and over 75 matched CLIA reagents.

The company's offerings encompass a diverse range of CLIA reagents, catering to various diagnostic needs including Thyroid, Fertility, Tumor Markers, Cardiac Markers, Inflammatory Markers, Reproductive function, Women & Kid Healthcare, and COVID-19 Detection. Notably, their MCL60 CLIA System supports on-the-fly calibration for whole blood & capillary blood tests, thus optimizing patient experience.

Roche Diagnostic has entered a significant partnership with RealMind, serving as the exclusive distributor for the MCL60 system in the Chinese Domestic market since November 2021. This collaboration is poised to enhance RealMind's market penetration and brand visibility.

Moreover, RealMind has been actively engaged in R&D, focusing on innovative IVD platforms including Immunoassay POC system, Next-Generation Flow Cytometry system, and electrowetting-on-dielectric (EWOD) POC system. These upcoming products are indicative of the company's commitment to advancing diagnostic technologies.

The startup recently secured a Seed Round investment in July 19, 2021, with notable investors including 华大共赢 BGI COWIN, Probe Capital, and Haibang Capital. This investment is a testament to the industry's confidence in RealMind's potential for growth and innovation.

Overall, RealMind Biotech's strategic positioning within the biotechnology sector and its strong focus on innovation and partnerships underline its potential to emerge as a key player in the global diagnostics market.